Dr. Christine Munz becomes CEO at Eppendorf
Dr. Wilhelm Plüster completes term in office as planned
Advertisement
The Supervisory Board of Eppendorf SE has appointed Dr. Christine Munz as the new CEO of the Eppendorf Group. On October 1, 2024, she will succeed Dr. Wilhelm Plüster who will now take on other strategically relevant responsibilities in the company as planned.
Dr. Christine Munz
Eppendorf
“We are very pleased that we were able to win Dr. Munz for Eppendorf and the CEO position,” said Philipp von Loeper, the Chairman of the Supervisory Board at Eppendorf SE. “On behalf of the entire Supervisory Board, I would also like to thank Dr. Plüster for his tremendous commitment to the company with which he has worked as CEO in the past few months. After serving more than 10 years on the Management Board of Eppendorf, he demonstrated once again his enormous dedication to the company. We are really pleased that he will remain at Eppendorf and assume another responsible position within the company.”
With Dr. Christine Munz Eppendorf will have a strong international experienced CEO, said von Loeper and added: “She is a proven and highly skilled manager with many years of experience in the life science industry. Working together with the global management team, Dr. Munz will continue to drive forward Eppendorf’s successful activities and expand them in a targeted manner.”
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Beckman Coulter Life Sciences Names Joe Fox President
Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases
GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026
Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership
WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership
Otto Warburg Medal 2026 awarded to Maya Schuldiner
Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research
New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments
CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need